ASCO 2025 | Evaluating the significance of ctDNA status in the NIAGARA trial
Jacqueline Brown, MD, Emory University School of Medicine, Atlanta, GA, describes the significance of the circulating tumor DNA (ctDNA) data from the NIAGARA trial (NCT03732677) of perioperative durvalumab with neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer (MIBC). Understanding its prognostic value is a crucial step towards its application in clinical practice. ctDNA has the potential to guide direct treatment decisions. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I really love seeing the circulating tumor DNA data from the NIAGARA study. We have this, you know, we’ve been getting circulating tumor DNA in our patients. We don’t really know how to apply it to clinical practice. Right now it mostly just causes anxiety for us and our patients because we might see it positive and not know what to do. So it was just helpful for being able to understand what ctDNA negativity and positivity means for those patients...
I really love seeing the circulating tumor DNA data from the NIAGARA study. We have this, you know, we’ve been getting circulating tumor DNA in our patients. We don’t really know how to apply it to clinical practice. Right now it mostly just causes anxiety for us and our patients because we might see it positive and not know what to do. So it was just helpful for being able to understand what ctDNA negativity and positivity means for those patients. I think we know it’s prognostic. Now we really have to figure out how to make it predictive and can we use it to sort of direct our treatment. So I was thrilled to see that. I’m excited to see Amplitude in the prostate cancer space and I’m just excited to see friends. Like this is a very fun outing. So just happy to be here.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
